Burn Wound Infections Medication
- Author: Jairo A Fonseca, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
The goals of antimicrobial therapy are to treat an underlying infection, to reduce morbidity, and to prevent mortality. Topical therapy is often applied to prevent infection and to treat ongoing infections or used as an adjunct to surgical treatment and systemic antibiotics. Systemic antimicrobial agents should be directed at the underlying pathogen recovered from culture or determined empirically from the local burn unit’s antibiogram while culture results are pending. If carbapenem resistance is confirmed for an isolated gram-negative bacteria, colistin should be considered.
Antifungal agents may also be used; however, pathogen identification is necessary to determine the ideal antifungal agent, as amphotericin B is not active against all fungal infections.
Topical therapy is typically applied to prevent infection and to treat infection when adequate surgical management is not possible.
Effective, safe, and reliable topical wash. Polybiguanide with bactericidal activity; usually supplied as a gluconate salt. At physiologic pH, the salt dissociates to a cation that binds to negatively charged bacterial cell walls and extramicrobial complex, causing bacteriostatic and bactericidal effects. Active against gram-positive and gram-negative organisms, facultative anaerobes, aerobes, and yeast.
Commercially available central venous catheters impregnated with chlorhexidine and silver sulfadiazine are available.
Silver sulfadiazine is useful in the prevention of infections from second- or third-degree burns. It has bactericidal activity against many gram-positive and gram-negative bacteria, including yeast. It has poor eschar penetration.
Silver nitrate coagulates cellular protein and removes granulation tissue. It exhibits activity against gram-positive bacteria, gram-negative bacteria, and candidal species. The major drawbacks are that it has poor penetration of eschar, requires the use of occlusive dressings, and turns black upon contact with tissues.
Mafenide is a topical sulfonamide. Through competitive inhibition of para-aminobenzoic acid, interferes with bacterial folic acid synthesis. It diffuses freely into the eschar and is highly effective against gram-negative organisms, including pseudomonal species.
Vaccine, Inactivated (Bacterial)
These agents are used for tetanus immunization. A booster injection against tetanus in previously immunized individuals is recommended to prevent this potentially lethal syndrome.
Tetanus immune globulin (TIG) is used for passive immunization of any person with a wound that may be contaminated with tetanus spores. Tetanus toxoid is used to induce active immunity against tetanus in selected patients. Burns are extremely tetanus-prone wounds. All burn patients with an incomplete immunization history should receive a dosage of tetanus toxoid (Td for adults or children >7 y, DTP or TD for children < 7 y). Children with up-to-date primary immunization series are considered to be up-to-date for tetanus immunization status. If the patient has a history of complete immunization and the last immunization with absorbed tetanus toxoid is within the last 5 years, further immunization is not required. If the history of tetanus immunization is unknown, both Td and TIG should be administered.
Used for passive immunization of any person with a wound that may be contaminated with tetanus spores.
Latenser BA, Miller SF, Bessey PQ, et al. National Burn Repository 2006: a ten-year review. J Burn Care Res. 2007 Sep-Oct. 28(5):635-58. [Medline].
Gomez R, Murray CK, Hospenthal DR, Cancio LC, Renz EM, Holcomb JB, et al. Causes of mortality by autopsy findings of combat casualties and civilian patients admitted to a burn unit. J Am Coll Surg. 2009 Mar. 208 (3):348-54. [Medline].
Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006 Apr. 19(2):403-34. [Medline].
Keen EF 3rd, Robinson BJ, Hospenthal DR, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns. September 2010. 36:819-25. [Medline].
Albrecht MC, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. October 2006. 203:546-50. [Medline].
Horvath EE, Murray CK, Vaughan GM, et al. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. Ann Surg. 2007 Jun. 245(6):978-85. [Medline]. [Full Text].
Sarabahi S, Tiwari VK, Arora S, Capoor MR, Pandey A. Changing pattern of fungal infection in burn patients. Burns. 2012 Jun. 38(4):520-8. [Medline].
Kasten KR, Makley AT, Kagan RJ. Update on the critical care management of severe burns. J Intensive Care Med. 2011 Jul-Aug. 26(4):223-36. [Medline].
Rowan MP, Cancio LC, Elster EA, Burmeister DM, Rose LF, Natesan S, et al. Burn wound healing and treatment: review and advancements. Crit Care. 2015 Jun 12. 19:243. [Medline].
Keen EF 3rd, Robinson BJ, Hospenthal DR, et al. Incidence and bacteriology of burn infections at a military burn center. Burns. 2010 Jun. 36(4):461-8. [Medline].
Kennedy P, Brammah S, Wills E. Burns, biofilm and a new appraisal of burn wound sepsis. Burns. 2010 Feb. 36(1):49-56. [Medline].
Schofield CM, Murray CK, Horvath EE, et al. Correlation of culture with histopathology in fungal burn wound colonization and infection. Burns. 2007 May. 33(3):341-6. [Medline].
Regules JA, Carlson MD, Wolf SE, Murray CK. Analysis of anaerobic blood cultures in burned patients. Burns. 2007 Aug. 33(5):561-4. [Medline].
American Burn Association. Burn Incidence and Treatment in the United States: 2016. Available at http://www.ameriburn.org/resources_factsheet.php. Accessed: 04/17/2016.
Peck M, Pressman MA. The correlation between burn mortality rates from fire and flame and economic status of countries. Burns. 2013 Sep. 39 (6):1054-9. [Medline].
Mistry RM, Pasisi L, Chong S, Stewart J, She RB. Socioeconomic deprivation and burns. Burns. 2010 May. 36(3):403-8. [Medline].
Mayhall CG. The epidemiology of burn wound infections: then and now. Clin Infect Dis. 2003 Aug 15. 37(4):543-50. [Medline].
Greenhalgh DG, Saffle JR, Holmes JH 4th, Gamelli RL, Palmieri TL, Horton JW. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007 Nov-Dec. 28(6):776-90. [Medline].
Kaiser ML, Thompson DJ, Malinoski D, Lane C, Cinat ME. Epidemiology and risk factors for hospital-acquired methicillin-resistant Staphylococcus aureus among burn patients. J Burn Care Res. 2011 May-Jun. 32(3):429-34. [Medline].
Shankar R, Melstrom KA Jr, Gamelli RL. Inflammation and sepsis: past, present, and the future. J Burn Care Res. 2007 Jul-Aug. 28(4):566-71. [Medline].
Schultz L, Walker SA, Elligsen M, Walker SE, Simor A, Mubareka S, et al. Identification of predictors of early infection in acute burn patients. Burns. 2013 Nov. 39 (7):1355-66. [Medline].
Murray CK, Hoffmaster RM, Schmit DR, Hospenthal DR, Ward JA, Cancio LC. Evaluation of white blood cell count, neutrophil percentage, and elevated temperature as predictors of bloodstream infection in burn patients. Arch Surg. 2007 Jul. 142(7):639-42. [Medline].
Rodriguez NA, Jeschke MG, Williams FN, Kamolz LP, Herndon DN. Nutrition in burns: Galveston contributions. JPEN J Parenter Enteral Nutr. 2011 Nov. 35(6):704-14. [Medline].
Eljaiek R, Dubois MJ. Hypoalbuminemia in the first 24h of admission is associated with organ dysfunction in burned patients. Burns. 2013 Feb. 39 (1):113-8. [Medline].
Lavrentieva A, Papadopoulou S, Kioumis J, Kaimakamis E, Bitzani M. PCT as a diagnostic and prognostic tool in burn patients. Whether time course has a role in monitoring sepsis treatment. Burns. 2012 May. 38(3):356-63. [Medline].
Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns. 2011 Jun. 37(4):549-58. [Medline].
Uppal SK, Ram S, Kwatra B, Garg S, Gupta R. Comparative evaluation of surface swab and quantitative full thickness wound biopsy culture in burn patients. Burns. 2007 Jun. 33(4):460-3. [Medline].
Ono S, Imai R, Ida Y, Shibata D, Komiya T, Matsumura H. Increased wound pH as an indicator of local wound infection in second degree burns. Burns. 2015 Jun. 41 (4):820-4. [Medline].
Lundy JB, Chung KK, Pamplin JC, Ainsworth CR, Jeng JC, Friedman BC. Update on Severe Burn Management for the Intensivist. J Intensive Care Med. 2015 Jun 24. [Medline].
Sevgi M, Toklu A, Vecchio D, Hamblin MR. Topical antimicrobials for burn infections - an update. Recent Pat Antiinfect Drug Discov. 2013 Dec. 8 (3):161-97. [Medline].
Barajas-Nava LA, López-Alcalde J, Roqué i Figuls M, Solà I, Bonfill Cosp X. Antibiotic prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev. 2013 Jun 6. 6:CD008738. [Medline].
Azzopardi EA, Azzopardi E, Camilleri L, Villapalos J, Boyce DE, Dziewulski P, et al. Gram negative wound infection in hospitalised adult burn patients--systematic review and metanalysis-. PLoS One. 2014. 9 (4):e95042. [Medline].
D'Avignon LC, Hogan BK, Murray CK, Loo FL, Hospenthal DR, Cancio LC, et al. Contribution of bacterial and viral infections to attributable mortality in patients with severe burns: an autopsy series. Burns. 2010 Sep. 36 (6):773-9. [Medline].
Azzopardi EA, Boyce DE, Thomas DW, Dickson WA. Colistin in burn intensive care: back to the future?. Burns. 2013 Feb. 39 (1):7-15. [Medline].
Chong SJ, Ahmed S, Tay JM, Song C, Tan TT. 5 year analysis of bacteriology culture in a tropical burns ICU. Burns. 2011 Dec. 37(8):1349-53. [Medline].
Pidcoke HF, Wade CE, Wolf SE. Insulin and the burned patient. Crit Care Med. 2007 Sep. 35(9 Suppl):S524-30. [Medline].
Breederveld RS, Tuinebreijer WE. Recombinant human growth hormone for treating burns and donor sites. Cochrane Database Syst Rev. 2014 Sep 15. 9:CD008990. [Medline].
Wolf SE. Nutrition and metabolism in burns: state of the science, 2007. J Burn Care Res. 2007 Jul-Aug. 28(4):572-6. [Medline].
Vicic VK, Radman M, Kovacic V. Early initiation of enteral nutrition improves outcomes in burn disease. Asia Pac J Clin Nutr. 2013. 22 (4):543-7. [Medline].
Abdullahi A, Jeschke MG. Nutrition and anabolic pharmacotherapies in the care of burn patients. Nutr Clin Pract. 2014 Oct. 29 (5):621-30. [Medline].
Melinyshyn A, Callum J, Jeschke MC, Cartotto R. Albumin supplementation for hypoalbuminemia following burns: unnecessary and costly!. J Burn Care Res. 2013 Jan-Feb. 34 (1):8-17. [Medline].
Lin JJ, Chung XJ, Yang CY, Lau HL. A meta-analysis of trials using the intention to treat principle for glutamine supplementation in critically ill patients with burn. Burns. 2013 Jun. 39 (4):565-70. [Medline].
Esselman PC. Burn rehabilitation: an overview. Arch Phys Med Rehabil. 2007 Dec. 88(12 Suppl 2):S3-6. [Medline].
Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns. 2006 Mar. 32(2):145-50. [Medline].
Ciofi Silva CL, Rossi LA, Canini SR, Gonçalves N, Furuya RK. Site of catheter insertion in burn patients and infection: a systematic review. Burns. 2014 May. 40 (3):365-73. [Medline].